Palvella Therapeutics (PVLA) News Today $29.00 +1.01 (+3.61%) As of 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Pavella - Undiscovered Biotechnology StockMarch 12 at 12:42 PM | msn.comPalvella Therapeutics (NASDAQ:PVLA) Earns Sector Outperform Rating from Analysts at ScotiabankMarch 10 at 1:57 AM | americanbankingnews.comScotiabank Initiates Coverage of Palvella Therapeutics (PVLA) with Sector Outperform RecommendationMarch 8, 2025 | msn.comPalvella Therapeutics (NASDAQ:PVLA) Coverage Initiated at ScotiabankScotiabank began coverage on shares of Palvella Therapeutics in a research report on Friday. They set a "sector outperform" rating and a $50.00 target price on the stock.March 8, 2025 | marketbeat.comBML Capital Management LLC Makes New Investment in Palvella Therapeutics (NASDAQ:PVLA)BML Capital Management LLC bought a new position in Palvella Therapeutics (NASDAQ:PVLA - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 42,130 shares of the company's stockMarch 8, 2025 | marketbeat.comPalvella Therapeutics initiated with an Outperform at ScotiabankMarch 7, 2025 | markets.businessinsider.comPositive Outlook on Palvella Therapeutics: Buy Rating Backed by Promising QTORIN Rapamycin PotentialMarch 7, 2025 | tipranks.comWhy These 15 Biotech Stocks Are Skyrocketing So Far In 2025March 3, 2025 | insidermonkey.comContrasting Palvella Therapeutics (PVLA) and Its PeersMarch 3, 2025 | americanbankingnews.comPalvella Therapeutics, Inc.March 2, 2025 | cnn.comWhy Palvella Therapeutics, Inc. (PVLA) is Skyrocketing So Far in 2025March 1, 2025 | msn.comCanaccord Genuity Group Reiterates "Buy" Rating for Palvella Therapeutics (NASDAQ:PVLA)Canaccord Genuity Group reissued a "buy" rating and set a $39.00 price objective on shares of Palvella Therapeutics in a research note on Wednesday.February 27, 2025 | marketbeat.comPalvella Therapeutics to Present at the TD Cowen 45th Annual Healthcare ConferenceFebruary 25, 2025 | globenewswire.comCanaccord Genuity Group Initiates Coverage on Palvella Therapeutics (NASDAQ:PVLA)Canaccord Genuity Group initiated coverage on shares of Palvella Therapeutics in a report on Thursday. They issued a "buy" rating and a $39.00 price target for the company.February 21, 2025 | marketbeat.comCanaccord starts Palvella Therapeutics with a Buy on lead programs’ potentialFebruary 21, 2025 | markets.businessinsider.comCanaccord Genuity Initiates Coverage of Palvella Therapeutics (PVLA) with Buy RecommendationFebruary 21, 2025 | msn.comPalvella Therapeutics initiated with a Buy at CanaccordFebruary 20, 2025 | markets.businessinsider.comH.C. WAINWRIGHT MAINTAINS BUY RATING, $38 TARGET ON PALVELLA STOCKFebruary 11, 2025 | msn.comAnalysts Offer Insights on Healthcare Companies: Palvella Therapeutics (PVLA) and Corcept Therapeutics (CORT)February 11, 2025 | markets.businessinsider.comPalvella Therapeutics (NASDAQ:PVLA) Given "Buy" Rating at HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $38.00 price objective on shares of Palvella Therapeutics in a research report on Tuesday.February 11, 2025 | marketbeat.comPalvella Therapeutics to expand Phase 3 SELVA trial to include younger patientsFebruary 10, 2025 | markets.businessinsider.comPalvella Therapeutics to Expand Phase 3 SELVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations to Include the Younger Pediatric Population, Children 3 to 5 Years OldFebruary 10, 2025 | globenewswire.comTD Cowen Initiates Coverage of Palvella Therapeutics (PVLA) with Buy RecommendationFebruary 5, 2025 | msn.comCowen initiates Palvella Therapeutics with buy, $44 targetFebruary 5, 2025 | msn.comTD Cowen Initiates Coverage on Palvella Therapeutics (NASDAQ:PVLA)TD Cowen started coverage on Palvella Therapeutics in a report on Wednesday. They set a "buy" rating and a $44.00 price objective for the company.February 5, 2025 | marketbeat.comPalvella Therapeutics initiated with a Buy at TD CowenFebruary 5, 2025 | markets.businessinsider.comPVLA Palvella Therapeutics, Inc.January 28, 2025 | seekingalpha.comPalvella Therapeutics, Inc. (PVLA)January 14, 2025 | finance.yahoo.comPalvella Therapeutics Reports Promising Results for QTORIN Rapamycin in Treating Rare Genetic DiseaseJanuary 12, 2025 | msn.comBuy Rating Affirmed for Palvella Therapeutics Amid Clinical Progress and Strong Financial PositionJanuary 10, 2025 | markets.businessinsider.comPalvella Therapeutics announces results from Phase 2 study of QTORINJanuary 10, 2025 | markets.businessinsider.comPalvella Therapeutics Kicks Off Phase 2 Trial for Promising Cutaneous VM TreatmentJanuary 9, 2025 | msn.comPalvella Therapeutics Inc PVLAJanuary 1, 2025 | morningstar.comInsider Buying: Palvella Therapeutics (NASDAQ:PVLA) Director Buys 4,000 Shares of StockDecember 20, 2024 | insidertrades.com Remove Ads Get Palvella Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PVLA and its competitors with MarketBeat's FREE daily newsletter. Email Address PVLA Media Mentions By Week PVLA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PVLA News Sentiment▼0.740.82▲Average Medical News Sentiment PVLA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PVLA Articles This Week▼93▲PVLA Articles Average Week Remove Ads Get Palvella Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PVLA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies XNCR News Today DAWN News Today PAHC News Today HROW News Today ETNB News Today ZYME News Today COLL News Today EOLS News Today COGT News Today RCKT News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PVLA) was last updated on 3/12/2025 by MarketBeat.com Staff From Our PartnersURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredTrump Orders 'National Digital Asset Stockpile'Trump Orders ‘National Digital Asset Stockpile’ THIS could be the coin they choose…Crypto 101 Media | SponsoredDOGE’s Next Move: Not what you thinkDonald Trump, Elon Musk and the Department of Government Efficiency have kept their word. Moving even faste...Weiss Ratings | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredYour Wealth is Under AttackHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredTrump doesn’t give a damnPorter Stansberry: “I met with Trump’s biggest backers… they’re scooping up these 10 stocks” I recently met...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Palvella Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share Palvella Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
